Serum Free Kappa/Lambda Light Chains

Effective February 12, 2024, St. Joseph's/Candler Laboratory will be transitioning Serum Free Light Chain testing from our reference lab to Serum N Latex Free Light Chain assay by Siemens Healthineers in-house. The new in-house Siemens assay is equivalent to the assay previously used and is FDA-cleared:

- As an aid in diagnosis and monitoring of Multiple Myeloma and AL Amyloidosis
- To aid in evaluation of Monoclonal Gammopathy of Undetermined Significance (MGUS).

This new in-house assay is based on multiple monoclonal antibodies targeting epitopes of the constant region of light chains which leads to more consistent results, compared to the previous method that only used polyclonal antisera. Although the assays are clinically comparable, **absolute values obtained are not interchangeable** for a given patient.

What does this mean for you and your patients?

Your patients will continue to have high quality testing from our laboratory. For new patients, there is no impact, as they will have a baseline set from the new assay.

For established patients:

- Once you receive new results utilizing the N Latex FLC assay, these will become the new baseline for your current patients.
- Numbers are **Not Interchangeable** with previous assay values. Once the lab transitions, please do not continue to compare new values to old results after the first re-set.
- If you have concerns about any results, please do not hesitate to reach out to the laboratory.
- Interpretation flow and sample result comparisons are available on the St. Joseph's/Candler Laboratory Test Menu website. (Kappa/Lambda Interpretation Flow and Sample Result)